The treatment of severe eosinophilic asthma has been revolutionised with the introduction of anti-interleukin (IL)-5 biological treatment. Anti-IL-5 biologics include mepolizumab, benralizumab and reslizumab, all of which target the IL-5 pathway; regulatory randomised controlled trials (RCTs) have shown that they are efficient in reducing exacerbation rates and the need for maintenance oral corticosteroids (mOCS) [1–6]. Real-life results from the use of anti-IL-5 biologics suggest that they have exceeded the expectations set by RCTs. Data from the nationwide Danish Severe Asthma Register (DSAR) showed that 58% of patients achieved a complete response with complete abrogation of the outcomes that set the indication for treatment: exacerbations and need for mOCS [7].

随着抗白细胞介素 (IL)-5 生物治疗的引入，严重嗜酸粒细胞性哮喘的治疗发生了革命性的变化。抗IL-5生物制剂包括美泊利珠单抗(mepolizumab)、贝那利珠单抗(benralizumab)和瑞利珠单抗(reslizumab)，它们都靶向IL-5通路；监管随机对照试验（RCT）表明，它们可以有效降低病情恶化率和维持口服皮质类固醇（mOCS）的需要[1-6]。使用抗 IL-5 生物制剂的实际结果表明，它们已经超出了随机对照试验设定的预期。来自全国丹麦严重哮喘登记处 (DSAR) 的数据显示，58% 的患者获得了完全缓解，完全消除了设定治疗指征的结果：病情加重和需要 mOCS [7]。